These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38647528)

  • 1. A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin.
    Chakraborty A; Onda M; O'Shea T; Wei J; Liu X; Bera TK; Pastan I
    Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38647528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin.
    Chakraborty A; Onda M; O'Shea T; Wei J; Liu X; Bera TK; Pastan I
    Mol Cancer Ther; 2024 Jun; ():OF1-OF10. PubMed ID: 38853444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
    Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
    Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
    Hatterer E; Chauchet X; Richard F; Barba L; Moine V; Chatel L; Broyer L; Pontini G; Bautzova T; Juan F; Calloud S; Bosson N; Charreton M; Masternak K; Buatois V; Shang L
    MAbs; 2020; 12(1):1739408. PubMed ID: 32191151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
    Chu GJ; Bailey CG; Nagarajah R; Liang O; Metierre C; Sagnella SM; Castelletti L; Yeo D; Adelstein S; Rasko JEJ
    Cytotherapy; 2024 Apr; 26(4):325-333. PubMed ID: 38349311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors.
    Grasso L; Jiang Q; Hassan R; Nicolaides NC; Kline JB
    Eur J Immunol; 2023 Aug; 53(8):e2250309. PubMed ID: 37146241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies.
    Gopalakrishnapillai A; Correnti CE; Pilat K; Lin I; Chan MK; Bandaranayake AD; Mehlin C; Kisielewski A; Hamill D; Kaeding AJ; Meshinchi S; Olson JM; Kolb EA; Barwe SP
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin.
    Liu X; Onda M; Watson N; Hassan R; Ho M; Bera TK; Wei J; Chakraborty A; Beers R; Zhou Q; Shajahan A; Azadi P; Zhan J; Xia D; Pastan I
    Proc Natl Acad Sci U S A; 2022 May; 119(19):e2202439119. PubMed ID: 35512094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
    Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer.
    Cao B; Liu M; Huang J; Zhou J; Li J; Lian H; Huang W; Guo Y; Yang S; Lin L; Cai M; Zhi C; Wu J; Liang L; Hu Y; Hu H; He J; Liang B; Zhao Q; Zhu K
    Int J Biol Sci; 2021; 17(14):3850-3861. PubMed ID: 34671203
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
    Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
    Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
    Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
    Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
    Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
    Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fully human antibody V
    Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
    Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
    Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin.
    Liu JJ; Pan ZD; Yue YL; Wang SS; Chen J; Jiang H; Zhang BH; Wu MY; Yuan YS; Bian YL; Yin HY; Wang L; Li JY; Gilly J; Xie YQ; Zhu JW
    Acta Pharmacol Sin; 2024 Oct; 45(10):2186-2198. PubMed ID: 38858494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
    DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
    Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells.
    El-Serafi I; Micallef Nilsson I; Moter A; Duan Z; Mattsson J; Magalhaes I
    Cancer Immunol Immunother; 2024 Jul; 73(9):163. PubMed ID: 38954005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.
    Snell D; Gunde T; Warmuth S; Chatterjee B; Brock M; Hess C; Johansson M; Simonin A; Spiga FM; Weinert C; Kirk N; Bassler N; Campos Carrascosa L; Flückiger N; Heiz R; Wagen S; Giezendanner N; Alberti A; Yaman Y; Mahler D; Diem D; Lichtlen P; Urech D
    Oncoimmunology; 2023; 12(1):2233401. PubMed ID: 37456982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
    Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
    Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.